Elevance Health Inc.

(New York Stock Exchange)
Back to all articles
Bullish +65

Elevance Health (NYSE:ELV) Shares Rise as Q3 Earnings Beat and Raised Outlook Offset Inline Revenue - ChartMill

Earnings report Guidance raised AI-generated analysis

πŸ“ˆ Elevance Health reported Q3 2026 revenue of $50.4 billion, which was approximately 1.5% above consensus estimates and described as inline with expectations.

πŸ’° Adjusted EPS surged to $6.99, a roughly 48% beat against the $4.73 consensus that drove the headline earnings surprise.

πŸ“‰ Revenue growth was partially offset by lower membership in Medicare Advantage, Medicaid, and Employer Group risk-based plans.

πŸ›‘οΈ The benefit expense ratio improved 70 basis points to 90.6% due to better performance in Medicare Advantage and Individual ACA segments.

πŸš€ Management raised its 2026 earnings outlook and remains confident in delivering at least 12% adjusted EPS growth for 2027.

πŸ“ˆ Shares rose about 2.2% in premarket trading, extending a strong recent run with gains over the last week, two weeks, and month.

πŸ’Ό Adjusted operating expenses increased slightly to 11.3% as the company invested in capabilities and growth initiatives.

Bullish Signals
  • Elevance Health delivered a massive adjusted EPS beat of roughly 48%, reporting $6.99 against a consensus of $4.73.
  • The company raised its 2026 earnings outlook and management remains confident in delivering at least 12% adjusted EPS growth for 2027.
  • Revenue came in slightly above estimates at $50.4 billion, driven by higher premium yields and increased CarelonRx product revenue.
  • The benefit expense ratio improved significantly by 70 basis points to 90.6%, reflecting better Medicare Advantage and Individual ACA performance.
  • Shares gained 2.2% in premarket trading, extending a strong recent trend with double-digit gains over the last two weeks.
Risk Factors
  • Revenue growth was partly offset by lower membership counts in Medicare Advantage, Medicaid, and Employer Group risk-based plans.
  • The adjusted operating expense ratio rose to 11.3% as the company made targeted one-time investments to support growth and quality initiatives.
  • Health Benefits operating gain declined year over year, indicating some pressure in that specific segment.
Full Analysis
Elevance Health (NYSE:ELV) reported third-quarter 2026 results where revenue of $50.4 billion came in slightly above consensus estimates, effectively inline with expectations at a 1.5% gap. However, the company delivered a significant profitability surprise with adjusted EPS of $6.99, representing a roughly 48% beat against the $4.73 consensus. This strong earnings performance drove shares higher in premarket trading as investors focused on the headline surprise despite the revenue result not being a blowout. The company attributed its financial strength to improved premium yields and growth in CarelonRx product revenue, which helped offset declines in Medicare Advantage, Medicaid, and Employer Group risk membership. Operating efficiency improved with the benefit expense ratio rising 70 basis points to 90.6%, aided by better performance in Medicare Advantage and Individual ACA segments. Management noted that adjusted operating expenses increased slightly due to targeted one-time investments aimed at supporting growth and quality initiatives. Management raised its 2026 earnings outlook and expressed confidence in delivering at least 12% adjusted EPS growth for 2027 from a higher baseline of at least $26.75. While this 2027 floor sits below the current analyst consensus for FY2026, the raised guidance and strong EPS beat were sufficient to support a 2.2% premarket gain. The stock has extended its recent strength with gains over the last week, two weeks, and month, suggesting the market is rewarding the earnings beat and positive outlook commentary.